Relmada Therapeutics Inc.

Aug 09, 2018

Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

Jun 27, 2018

Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder

Apr 03, 2018

Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer

Jan 17, 2018

Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

Jan 09, 2018

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

Oct 27, 2017

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

Oct 05, 2017

Relmada Therapeutics Announces $6.9 Million Private Placement

Jun 28, 2017

Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program

Jun 21, 2017

Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics

Jun 15, 2017

Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors